8-K: Tempus AI Files Prospectus for Resale of 1.27M Shares

Tempus AI, Inc. filed a prospectus supplement covering the resale of up to 1,268,033 shares of its Class A common stock by selling stockholders.

Summary

• Tempus AI, Inc. filed a Current Report on Form 8-K on August 27, 2025.
• A prospectus supplement was filed on August 27, 2025, covering the resale of up to 1,268,033 shares of Class A common stock by selling stockholders.
• This action follows an automatic shelf registration statement on Form S-3 (File No. 333-289398) filed on August 8, 2025.
• The shares for resale originate from three agreements dated August 22, 2025: a Merger Agreement (1,124,714 shares, including 85,966 holdback shares), a License Agreement (17,915 shares), and a Settlement and Release Agreement (125,404 shares).
• The filing includes a legal opinion from Brownstein Hyatt Farber Schreck, LLP, confirming the legality of the Class A common stock covered by the prospectus supplement.

Sentiment

Score: 6

Explanation: The filing is largely procedural, confirming the legality of shares for resale. It's slightly positive as it completes a necessary step for selling stockholders and confirms the validity of shares issued in recent strategic transactions (merger, license, settlement).

Positives

• The legal opinion confirms that the Class A common stock covered by the prospectus supplement has been duly authorized, validly issued, is fully paid, and non-assessable, which is a necessary step for facilitating resale.
• Completion of the required legal and regulatory steps for selling stockholders to resell their shares provides clarity and market access.

Future Outlook

The filing facilitates the future resale of shares by selling stockholders but does not provide any forward-looking statements regarding the company's operational performance, financial guidance, or strategic initiatives beyond the completion of these procedural steps.

Industry Context

The underlying transactions (merger with Paige.AI, license with Memorial Sloan-Kettering Cancer Center, and a settlement agreement) indicate Tempus AI's continued strategic expansion and collaboration within the AI-driven healthcare and cancer research sectors. This filing is a procedural step to enable the liquidity of shares issued as part of these strategic initiatives.

Stakeholder Impact

• Selling stockholders: Gain the ability to resell their shares in the market.
• Company: Completes a necessary legal and regulatory step for shares previously issued in strategic transactions.
• Investors: Provides transparency regarding the availability of shares for resale, which could impact market liquidity.

Next Steps

• Selling stockholders may proceed with the resale of up to 1,268,033 Class A common shares as covered by the prospectus supplement.

Key Dates

Keywords

Tempus AI, TEM, Class A common stock, share resale, prospectus supplement, SEC filing, Form S-3, Merger Agreement, License Agreement, Settlement Agreement, Paige.AI, Memorial Sloan-Kettering Cancer Center